Weekly shot could help people with short bowel syndrome absorb more fluids
NCT ID NCT07704047
First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time
Summary
This phase IIa trial tests whether FT1, a lab-made version of a natural gut hormone, is safe and helps reduce fluid loss in adults with short bowel syndrome. Participants receive weekly injections of FT1 or a placebo for five weeks. The study measures changes in stool weight and urine output to see if the drug improves fluid absorption.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a recombinant GLP-2 analog called FT1
- What this could lead to
- If successful, FT1 could become a new weekly injection to help people with short bowel syndrome absorb more fluids and nutrients, reducing their dependence on intravenous support.
- What could go wrong
- This is a small, early-phase trial with only 8 participants, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful benefit over placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SBS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
General Hospital of Eastern Theater Command
RECRUITINGNanjing, Jiangsu, 210002, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Measuring hidden energy needs: a clue to better nutrition for gut failure patients
- New drug could cut IV nutrition needs for short bowel patients
- Could a Plant-Based powder cut the need for IV nutrition?
- Growth hormone shows promise for weaning kids off IV nutrition
- New drug teduglutide monitored in 250 patients with short bowel syndrome
- New shot could cut IV feeding for short bowel patients